PATENT CLAIM ANALYSIS

Application Number: 16129311
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "002100"]

Abstract:
This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.

Claim (Index 12):
The method according to  claim 1 , wherein the disease or condition is further associated with Parkinson's disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Amyotrophic lateral sclerosis (ALS), cerebral palsy, stroke, traumatic brain injury (TBI), clozapine induced hypersalivation, Rett syndrome, Angelman syndrome, epileptic encephalopathy and brain tumours, total pharyngolaryngectomy, supracricoid laryngectomy and supraglottic laryngectomy, dementia, or intellectual disability.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 97.0
- Lexical Diversity: 1.30769
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['11795210', '14945804', '14166434', '15735417', '11156502']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7722369165146574
- 35 USC 102 Novelty (BERT): 0.5000127546043319
- Combined Prediction Score: 0.7450145003236249
- Mean Citation Score: 247.511704
- Max Citation Score: 259.13467
- Similarity Product: 201.11844348197343

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test